ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yoh Watanabe
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohta, Y.
Right arrow Articles by Watanabe, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohta, Y.
Right arrow Articles by Watanabe, Y.

Ann Thorac Surg 2000;69:1025-1029
© 2000 The Society of Thoracic Surgeons

ORIGINAL ARTICLES: GENERAL THORACIC

Clinicopathological and biological assessment of lung cancers with pleural dissemination

Yasuhiko Ohta, MDa, Yoko Tanaka, PhDa, Takuo Hara, MDa, Makoto Oda, MDa, Shun-ichi Watanabe, MDa, Junzo Shimizu, MDa, Yoh Watanabe, MDa

a First Department of Surgery, Kanazawa University School of Medicine, Kanazawa, Japan

Address reprint requests to Dr Ohta, First Department of Surgery, Kanazawa University School of Medicine, Takara-machi 13-1, Kanazawa 920-8641, Japan
e-mail: yohta{at}med.kanazawa-u.ac.jp

Background. This study provides the surgical outcome of lung cancer patients with pleural dissemination, with the assessment of the clinicopathological and biological prognostic factors.

Methods. Forty-three patients who underwent operations were studied. Vascular endothelial growth factor (VEGF) and autocrine motility factor receptor (AMFR/gp78) expression was immunohistochemically evaluated.

Results. In total, the overall 3 and 5-year survival rates were 31.4% and 13.1%, respectively. The patients who underwent the pleuropneumonectomy had a worse outcome than those who underwent limited operations (pleurectomy plus parenchymal resections were less than pneumonectomy). VEGF and AMFR/gp78 were highly expressed in primary tumors. Among the patients who underwent limited operations, pathological types other than adenocarcinoma and high expression of VEGF were significantly associated with a worse outcome. The pathological type was the only characteristic to retain a significant independent prognostic impact on overall survival.

Conclusions. The results imply the validation of limited operation for lung cancer with pleural dissemination for the local control. High frequency of VEGF and AMFR/gp78 expression conform to the interpretation that patients with pleural dissemination have a high-risk of systemic disease.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
M. Riquet, C. Foucault, and F. Souilamas
Lung cancer with pleural dissemination: why not operation?
Ann. Thorac. Surg., November 1, 2002; 74(5): 1750 - 1750.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. Sawabata
Reply
Ann. Thorac. Surg., November 1, 2002; 74(5): 1750 - 1750.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.